

Anakinra for treating Still's disease

Information for the public

Published: 31 March 2021

www.nice.org.uk

Anakinra (Kineret) is available on the NHS as a possible treatment for Still's disease with moderate to high disease activity, or continued disease activity after non-steroidal anti-inflammatory drugs or glucocorticoids. It is only recommended for:

- adult-onset Still's disease that has responded inadequately to 2 or more conventional disease-modifying antirheumatic drugs (DMARDs)
- systemic juvenile idiopathic arthritis in people 8 months and older with a body weight of 10 kg or more that has not responded to at least 1 conventional DMARD.

If you are not eligible for anakinra but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

This organisation can give you advice and support: [Rare Autoinflammatory Conditions Community-UK \(RACC-UK\)](#), 07377 091552.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4069-1